Dibutyl phthalate |CAS 84-74-2|DC Chemicals

Cas No.:	84-74-2
Chemical Name:	Dibutyl phthalate
Synonyms:	Dibutyl phthalate;1,2-benzenedicarboxylic acid dibutyl ester;ARALDITE RESIN;Benzenedicarboxylic acid dibutyl ester;DBP;DBP(R);DIBUTYL 1,2-BENZENEDICARBOXYLATE;DI-N-BUTYL PHTHALATE;DL-N-BUTYL PHTHALATE;N-BUTYL PHTHALATE;O-BENZENEDICARBOXYLIC ACID DIBUTYL ESTER;PHTHALIC ACID, BIS-BUTYL ESTER;PHTHALIC ACID DIBUTYL ESTER;PHTHALIC ACID DI-N-BUTYL ESTER;ai-3-00283;benzene-1,2-dicarboxylicaciddibutylester;Benzene-o-dicarboxylic acid, di-n-butyl ester;Bufa;1,2-Benzenedicarboxylic acid;Dibutyl phthalate solution;Dibutyl Phthalate-13C6,d4;Di-n-butyl phthalate (DBP);Di-n-butyl phthalate solution;Phthalic acid butyl ester;1,2-dibutyl 1,2-benzenedicarboxylate;1000μg;2,6-di-t-butyl-4-methyl-phenol;butyl dibutylphosphinate;butyl phthalate;Butylester of dibutylphosphinic acid;dibutyl benzene-1,2-dicarboxylate;dibutyl-phosphinic acid butyl ester;Dibutylphosphinsaeure-butylester;dibutylphosphonic acid butyl ester;Phosphinic acid,dibutyl-,butyl ester;Celluflex DPB;Elaol;Genoplast B;Palatinol C;Polycizer DBP;Unimoll DB;DIBUTYLPHTHALATE;Dibutyl-o-phthalate;Staflex DBP;Hexaplas M/B;Ergoplast FDB;Kodaflex DBP;DBP (ester);N-Butylphthalate;Ersoplast FDA;Phthalate, di-n-butyl;Uniflex DBP;Hatcol DBP;Dibutyl o-phthalate;RC Plasticizer DBP;1,2-Benzenedicarboxylic ac;Palatinol DBP;dibutyl phthalate; DBP;Phthalic acid di-n-butyl ester;Butyl phthalate;DIBUTYL PHTHALATE (II);KBio2_002532;DIBUTYL PHTHALATE [USP-RS];Uniplex 150;NA9095;CHEBI:34687;S5377;KBioGR_001267;NCGC00254882-01;di-n-butyl phthalate (dbp);HSDB 922;Dibutyl-1,2-benzenedicarboxylate;BDBM50371946;NSC 6370;2286E5R2KE;MLS002177802;KBio2_007668;Di(n-butyl) 1,2-benzenedicarboxylate;Ruifeng vp 201;ortho-Dibutyl phthalate;CS-0013564;CHEMBL272485;Bisoflex DBP;Ftalato di n-butanolo;Dibutyl phthalate, >=99%;Dibutyl phthalate, United States Pharmacopeia (USP) Reference Standard;Phthalic acid dibutyl ester;Dibutyl phthalate, PESTANAL(R), analytical standard;NCGC00090769-08;SpecPlus_000628;BRN 1914064;Dibutyl phthalate [NF];DB13716;NCGC00090769-01;Di(1-butyl) phthalate;Dibutyl-1,2-benzene-dicarboxylate;SMR000777923;Dibutyl phthalate, SAJ special grade, >=98.0%;KBio3_002047;Benzol-1,2-dicarbonsauredibutylester;Q415612;Witcizer 300;RAPIDCELLtrade markP;HMS3041E18;Phthalic acid, dibutyl ester;Dibutyl 1, 2-benzenedicarboxylate;NCGC00259278-01;Dibutyl Phthalate, Pharmaceutical Secondary Standard; Certified Reference Material;Benzene-o-dicarboxylic acid di-n-butyl ester;Dibutyl 1,2-benzene-dicarboxylate;Dibutylftalat;Ersoplast FDA.;dibutyl phthalate;Dibutyl phthalate, LR, >=98%;Di-n-butyl phthalate;Phthalic acid, bis-butyl ester;Di n Butyl Phthalate;RCRA waste number U069;SR-05000001549-3;DIBUTYL PHTHALATE [MART.];DIBUTYL PHTHALATE (SEE ALSO PEROXISOME PROJECT (DIBUTYL PHTHALATE));Phthalate, Dibutyl;di-n-butyl phthalate (DBuP);Sicol 140;Dibutyl phthalate, Selectophore(TM);o-Benzenedicarboxylic acid, dibutyl ester;D...
SMILES:	O=C(C1C(C(OCCCC)=O)=CC=CC=1)OCCCC
Formula:	C₁₆H₂₂O₄
M.Wt:	278.343485355377
Purity:	>98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Description:

In Vitro Dibutyl phthalate (0.001 µg/mL-1000 µg/mL) is detrimental to follicle growth and viability and results in significant dysregulation of cell cycle and apoptosis gene expression in a dose-specific manner. But MBP does not play a role in Dibutyl phthalate toxicity in follicles exposed in vitro. In Vivo Dibutyl phthalate (200, 400, or 600 mg/kg/day) induces decrease mice weight, impairment of spermatogenesis, reduces serum follicle stimulating hormone and testosterone level, alters testicular LDH, increases LPO, and decreases the levels of enzymatic antioxidants with histopathological anomalies. Dibutyl phthalate (6.25, 12.5, 25, 50, 100 and 200 mg/kg) could cause some neurobehavioral adverse effects in mice.

MSDS

COA

LOT NO.	DOWNLOAD

2018-0101

Cat. No.	Product name	Field of application
DC31074	Isopropyl myristate	Isopropyl myristate is the ester of isopropyl alcohol and myristic acid.
DC75868	AZ14133346	AZ14133346 (compound 36) is a potent and selective inhibitor of EGFR Exon20 insertions, with the IC50 of 85 nM. AZ14133346 plays an important role in cancer research.
DC75865	TI17	TI17 represents a novel class of targeted anticancer agents that specifically disrupt DNA damage repair mechanisms in malignant cells.
DC75816	Nisoxetine	Nisoxetine acts as a highly selective and potent noradrenaline transporter (NET) antagonist, exhibiting a binding affinity (Kd) of 0.76 nM. In addition to its antidepressant properties, nisoxetine functions as a local anesthetic by inhibiting voltage-gated sodium channels. This dual pharmacological activity makes it a compound of interest for both neurological and pain management research.
DC75202	Fosaprepitant free acid	Fosaprepitant, also known as MK0517, is an antiemetic drug, administered intravenously. It is a prodrug of aprepitant. Fosaprepitant was developed by Merck & Co. and was approved. It is a prodrug of Aprepitant. It aids in the prevention of acute and delayed nausea and vomiting associated with chemotherapy treatment. Fosaprepitant is a weak inhibitor of CYP3A4, and aprepitant, the active moiety, is a substrate, inhibitor, and inducer of CYP3A4
DC74684	ZH8667	ZH8667 is a trace amine-associated receptor 1 (TAAR1)–Gs agonist.
DC74646	EB-PSMA-617	EB-PSMA-617 is an Evans blue-modified prostate-specific membrane antigen (PSMA) 617 ligand for making 177Lu-EB-PSMA, which is potential useful for Metastatic Castration-Resistant Prostate Cancer.
DC74641	HC-258	HC-258 is a Covalent Acrylamide TEAD Inhibitor That Reduces Gene Expression and Cell Migration. HC-258 reduces the CTGF, CYR61, AXL, and NF2 transcript levels and inhibits the migration of MDA-MB-231 breast cancer cells. Co-crystallization with hTEAD2 confirmed that HC-258 binds within TEAD’s PA pocket, where it forms a covalent bond with its cysteine.
DC74639	Oligopeptide-10	Oligopeptide-10, also known as granactive oligopeptide-10, is a synthetic bio-active peptide composed of 15 amino acids. it can help manage acne-causing bacteria, both on its own and in conjunction with anti-acne superstar exfoliant salicylic acid.
DC74638	GLPG3667	GLPG3667 is an oral, reversible, and selective tyrosine kinase 2 (TYK2) inhibitor. It is being developed to treat inflammatory and auto-immune diseases. Biochemical assays showed that GLPG3667 displayed nanomolar potency on TYK2 with a selectivity over other JAK kinases >3-fold. In human PBMC, GLPG3667 showed comparable potency on the IFNα and IL-23 pathways (around 50 nM). Selectivity for TYK2 on the IFNα pathway was >14-fold and >19-fold toward the IL-2 and GM-CSF pathways in human PBMC and whole blood, respectively. Dermal ear inflammation in a mouse model of psoriasis driven by IL-23 was prevented by GLPG3667 with a minimal effective dose of 3 mg/kg given orally once daily. This effect was associated with a decrease in neutrophil infiltration and STAT3 phosphorylation at sites of inflammation. In healthy HV, GLPG3667 completely inhibited IFNα-induced STAT1 and STAT3 phosphorylation but did not impact IL-2- and GM-CSF-induced STAT5 phosphorylation.